GILEAD SCIENCES, INC.
GILEAD SCIENCES, INC. (GILD) Stock News
The latest GILD headlines and market coverage — 5 recent stories, updated throughout the day.
- Zacks Investment Research·Neutral
Gilead Sciences (GILD) Laps the Stock Market: Here's Why
Gilead Sciences (GILD) closed at $151.17, up 2.77% and outperforming the S&P 500. The HIV and hepatitis C drugmaker is expected to report a 13.36% EPS decline for the upcoming quarter, though revenue is projected to increase 0.51%. The stock holds a Zacks Rank #3 (Hold) rating, with the Medical - Biomedical and Genetics industry ranked 177th out of 250+ industries.
- Zacks Investment Research·
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences stock declined 1.87% to $144.74 while broader markets gained, underperforming the S&P 500's 0.73% rise. The HIV and hepatitis C drugmaker has lost 2.46% over the past month, with the Medical sector down 3.74%. Upcoming earnings are projected at $2.15 per share (down 12.96% year-over-year) with revenue expected at $7.79 billion (up 0.3%). The stock holds a Zacks Rank #3 (Hold) rating.
- Zacks Investment Research·Neutral
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead Sciences (GILD), an HIV and hepatitis C drugmaker, is a trending stock with mixed fundamentals. The company maintains a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the broader market. While Gilead has beaten consensus estimates in the last four quarters and shows modest revenue growth forecasts of 4.4% and 6.1% for the current and next fiscal years, earnings estimates remain challenged with a projected -105.9% year-over-year change for the current fiscal year. The stock is valued at par with its peers.
- Zacks Investment Research·
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
Gilead Sciences declined 1.21% on September 30, 2026, underperforming the S&P 500's 0.25% loss. The HIV and hepatitis C drugmaker faces headwinds with projected quarterly EPS down 12.96% year-over-year, though revenue is expected to rise slightly by 0.3%. The company holds a Zacks Rank #3 (Hold) rating with consensus EPS estimates revised 2.2% lower over the past month.
- Zacks Investment Research·
Wall Street Analysts See Gilead (GILD) as a Buy: Should You Invest?
The article compares brokerage analyst recommendations (ABR) with Zacks Rank, arguing that while Gilead Sciences has a strong Buy-equivalent ABR of 1.52 from 31 firms, brokerage recommendations suffer from positive bias due to institutional conflicts of interest. The Zacks Rank, based on earnings estimate revisions rather than analyst opinions, is presented as a more reliable predictor of near-term stock performance. Gilead received a Zacks Rank #1 (Strong Buy) rating due to a 40.4% increase in consensus earnings estimates over the past month.